| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Across the last three months, Bolt Biotherapeutics, Inc.'s insiders have reduced their positions by a net 38,584 shares worth roughly $128K.
Classified under Biotechnology (Health Care sector), BOLT's insider flows are most useful compared with peers in the same group.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Other | 85.8K | - | - | |
| CEO | 25.4K | $82.2K | - | |
| COO | 17.3K | $55.9K | - | |
| VP | 17.1K | $55.3K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Feb 9, 2021 | Vivo Capital Viii, LLC57 | 10% Owner | Sell | 226 | $20.00 | $4,520.00 | - | |
| Feb 9, 2021 | Shah Mahendra | Director | Sell | 62 | $20.00 | $1,240.00 | - | |
| Feb 9, 2021 | Engleman Edgar60 | Director, 10% Owner | Sell | 164 | $20.00 | $3,280.00 | - | |
| Feb 9, 2021 | Vivo Capital Viii, LLC57 | 10% Owner | Buy | 350,000 | $20.00 | $7,000,000.00 | -175.0% | |
| Feb 9, 2021 | Laporte Kathleen | Director | Buy | 1,200 | $20.00 | $24,000.00 | New | |
| Feb 9, 2021 | Healy James | Director | Buy | 450,000 | $20.00 | $9,000,000.00 | +19.5% | |
| Feb 9, 2021 | Khanna Ashish Siri Ram | Director | Buy | 2,200 | $20.00 | $44,000.00 | -220.0% | |
| Feb 9, 2021 | Engleman Edgar60 | Director, 10% Owner | Buy | 200,000 | $20.00 | $4,000,000.00 | +263.9% | |
| Feb 9, 2021 | Quinn William P. | Chief Financial Officer | Buy | 1,200 | $20.00 | $24,000.00 | +9.5% | |
| Feb 9, 2021 | Schatzman Randall C | Chief Executive Officer | Buy | 1,500 | $20.00 | $30,000.00 | New |